

compared. Direct cost analysis of the test used was also performed.

**Results** 80 women were included. Seventeen patients were managed expectantly and 63 patients underwent surgery. 23 masses were malignant. Diagnostic performance of all three approaches is shown in table. Both US expert examination and MRI had significantly better diagnostic performance than ROMA. There was no difference in terms of diagnostic performance between US and MRI. Direct costs were significantly lower for US than for MRI and similar to ROMA

**Conclusion** US expert examination is the best second step approach in inconclusive adnexal masses as determined by IOTA Simple Rules

2022-RA-1682-ESGO **DIAGNOSTIC ACCURACY OF THREE-DIMENSIONAL TRANSVAGINAL ULTRASOUND FOR DETECTING CONGENITAL UTERINE ANOMALIES: SYSTEMATIC REVIEW AND META-ANALYSIS**

<sup>1</sup>Isabel Brotons Almandoz, <sup>2</sup>Julio Vara García, <sup>3</sup>Isabel Carriles Rivero, <sup>2</sup>Juan Luis Alcázar Zambrano. <sup>1</sup>Gynaecology, Clínica Universidad de Navarra, Pamplona, Spain; <sup>2</sup>Clínica Universidad de Navarra, Pamplona, Spain; <sup>3</sup>Clínica Universidad de Navarra, Madrid, Spain

10.1136/ijgc-2022-ESGO.188

**Introduction/Background** The aim of this study is to evaluate the accuracy of three-dimensional transvaginal ultrasound (3D-TVS) for the diagnosis of uterine mullerian anomalies (UMA), using surgery as the reference standard.

**Methodology** A search was performed in PubMed/MEDLINE, CINAHL, Scopus, Cochrane and Web of Science databases (January 1990 to December 2021) for studies evaluating the diagnostic performance of 3D-TVS for detecting UMA, using endoscopic findings as reference test. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used to evaluate the quality of the studies. Pooled sensitivity, specificity, positive and negative likelihood ratio for 3D-TVS were calculated for all types of anomalies and separately for septate and bicornuate uterus, specifically. Arcuate uterus was considered as normal. Post-test probability of detecting UMA following a positive or negative test was determined.

**Abstract 2022-RA-1682-ESGO Table 1** Diagnostic accuracy 3D-TVS for detecting UMA

Diagnostic accuracy of 3D-TVS for detecting UMA.

3D TVS	Sensitivity	Specificity	LR+	LR -
Any UMA	99% (95% CI. 97-100%)	100% (95% CI. 97-100%)	294 (95% CI. 36-2404)	0.01 (95% CI. 0.00-0.04)
Septate uterus	97% (95% CI. 94-99%)	100% (95% CI. 72-100%)	301 (95% CI. 2.5-36248.2)	0.03 (95% CI. 0.01-0.08)
Bicornuate uterus	95% (95% CI. 92-97%)	99% (95% CI. 97-100%)	29 (95% CI. 3.6-1009.2)	0.06 (95% CI. 0.03-0.09)

**Results** The search identified 297 citations after excluding duplicates. After further exclusions, fourteen studies were ultimately included in the qualitative and quantitative syntheses, comprising 1776 women. Fourteen studies analyzed the presence of any type of UMA and seven by subgroups (septate uterus and/or bicornuate uterus). The mean prevalence of UMA was 47% (range: 1%-97%). Overall, pooled sensitivity, specificity, positive and negative likelihood ratios are shown in table

1. Heterogeneity was high. According to the QUADAS-2 tool, most of the studies were considered high risk of bias for patient selection, and low risk for index test and reference standard and unclear for flow/timing.

**Conclusion** Our results confirm the high accuracy of 3D-TVS for diagnosing uterine mullerian anomalies. These data support the role of this technique as gold standard for detecting these anomalies

2022-RA-1687-ESGO **DIAGNOSTIC DIFFICULTIES IN LOW-GRADE ENDOMETRIAL STROMAL SARCOMA: REVIEW OF THE LITERATURE IN ONE CASE**

Meukem Tatsapie Wilfried Loïc, Uzan Jennifer, Yann Salhi, Jeremie Benichou, Morgane Blot Dupin, Pierre Andre Mal, Lecarpentier Edouard. *Gynecologie obstétrique, Centre Hospitalier Intercommunal De Créteil, Paris, France*

10.1136/ijgc-2022-ESGO.189

**Introduction/Background** Endometrial stromal sarcoma (ESS) is a rare and difficult to diagnose endometrial proliferation. It constitutes only about 0.2% of all uterine malignancies and is usually associated with a poor prognosis. SSE is usually misdiagnosed as a leiomyoma sometimes associated with a polyp. Both have nonspecific symptoms, which makes the diagnosis even more complex. Given the rarity of this neoplastic entity, the optimal management is quite dynamic and debatable

**Methodology** our study is a case report

**Results** We report here a rare case of a 35-year-old patient who presented for pregnancy with a presumptive diagnosis of leiomyoma, principle diagnostic hysteroscopy for cavity assessment in the context of infertility revealed a fundal imprint of a FIGO 2-5 myoma associated with an endocavitary process similar to a necrotic myoma which was resected two weeks later over a larger area of implantation compared to the time of diagnosis. Pathological analysis revealed a low-grade endometrial stromal sarcoma of 5.5 cm long axis, infiltrating >50% of the myometrium. As a result, the treatment plan was changed from conservative myomectomy to total interovarian hysterectomy.

**Conclusion** The aim of this case report is to highlight this uncommon tumour in young patients and to raise awareness of the need to consider this diagnosis, particularly when presenting with a rapidly enlarging uterine leiomyoma.

2022-RA-1700-ESGO **NEW ULTRASONOGRAPHIC MARKERS OF BORDERLINE OVARIAN TUMOURS (BOT)**

<sup>1,2</sup>Nadiezha Rodriguez, <sup>1</sup>Nicolas Rodriguez, <sup>1</sup>Nathalia Ayala, <sup>2,3</sup>Catalina Buritica, <sup>2</sup>Camila Saravia, <sup>2</sup>Ángela Nastar, <sup>2</sup>Natalia Ramirez, <sup>1,2</sup>Alba Esquivel. <sup>1</sup>Gynaecology, Fundacion Santa Fe de Bogota, Bogota, Colombia; <sup>2</sup>School of medicine, Universidad de los Andes, Bogota, Colombia; <sup>3</sup>Pathology, Fundacion Santa Fe de Bogota, Bogota, Colombia

10.1136/ijgc-2022-ESGO.190

**Introduction/Background** The most common signs of BOT on ultrasound (US) are reported to be: a septate cyst with solid component and/or mural nodules containing blood vessels in papillary projections. However, we describe ultrasonographic markers additional for the diagnosis of BOT

**Methodology** A retrospective study at a tertiary referral university hospital with a gynaecological oncology unit, from patients who underwent surgery between 2012 and 2022 with